Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.

Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW.

Br J Cancer. 2019 Jul 30. doi: 10.1038/s41416-019-0534-2. [Epub ahead of print]

PMID:
31363170
2.

The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy.

Reader CS, Vallath S, Steele CW, Haider S, Brentnall A, Desai A, Moore KM, Jamieson NB, Chang D, Bailey P, Scarpa A, Lawlor R, Chelala C, Keyse SM, Biankin A, Morton JP, Evans TJ, Barry ST, Sansom OJ, Kocher HM, Marshall JF.

J Pathol. 2019 Jul 1. doi: 10.1002/path.5320. [Epub ahead of print]

PMID:
31259422
3.

Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.

Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW.

Br J Cancer. 2019 Jul;121(3):218-221. doi: 10.1038/s41416-019-0506-6. Epub 2019 Jun 28. Erratum in: Br J Cancer. 2019 Jul 30;:.

PMID:
31249394
4.

Anti-aging interventions affect lifespan variability in sex, strain, diet and drug dependent fashion.

Bartke A, Evans TR, Musters CJM.

Aging (Albany NY). 2019 Jun 24;11(12):4066-4074. doi: 10.18632/aging.102037.

5.

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.

Twelves C, Anthoney A, Savulsky CI, Guo M, Reyderman L, Cresti N, Semiglazov V, Timcheva C, Zubairi I, Morrison R, Plummer R, Evans TRJ.

Br J Cancer. 2019 Mar;120(6):579-586. doi: 10.1038/s41416-018-0366-5. Epub 2019 Feb 20.

6.

Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury.

Neves KB, Rios FJ, Jones R, Evans TRJ, Montezano AC, Touyz RM.

Cardiovasc Res. 2019 Apr 15;115(5):978-988. doi: 10.1093/cvr/cvz021.

7.

A conceptual replication of emotional intelligence as a second-stratum factor of intelligence.

Evans TR, Hughes DJ, Steptoe-Warren G.

Emotion. 2019 Feb 7. doi: 10.1037/emo0000569. [Epub ahead of print]

PMID:
30730169
8.

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.

Evans TRJ, Dean E, Molife LR, Lopez J, Ranson M, El-Khouly F, Zubairi I, Savulsky C, Reyderman L, Jia Y, Sweeting L, Greystoke A, Barriuso J, Kristeleit R.

Br J Cancer. 2019 Feb;120(4):379-386. doi: 10.1038/s41416-019-0377-x. Epub 2019 Jan 25.

PMID:
30679780
9.

Putting 'Emotional Intelligences' in Their Place: Introducing the Integrated Model of Affect-Related Individual Differences.

Hughes DJ, Evans TR.

Front Psychol. 2018 Nov 14;9:2155. doi: 10.3389/fpsyg.2018.02155. eCollection 2018. Review.

10.

Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine.

Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P.

Gut. 2019 Apr;68(4):742-758. doi: 10.1136/gutjnl-2018-316822. Epub 2018 Nov 5. Review.

11.

Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme.

Lindsay CR, Shaw EC, Blackhall F, Blyth KG, Brenton JD, Chaturvedi A, Clarke N, Dick C, Evans TRJ, Hall G, Hanby AM, Harrison DJ, Johnston SRD, Mason MD, Morton D, Newton-Bishop J, Nicholson AG, Oien KA, Popat S, Rassl D, Sharpe R, Taniere P, Walker I, Wallace WA, West NP, Butler R, Gonzalez de Castro D, Griffiths M, Johnson PWM.

ESMO Open. 2018 Sep 5;3(6):e000408. doi: 10.1136/esmoopen-2018-000408. eCollection 2018.

12.

Detection of circulating tumour cell clusters in human glioblastoma.

Krol I, Castro-Giner F, Maurer M, Gkountela S, Szczerba BM, Scherrer R, Coleman N, Carreira S, Bachmann F, Anderson S, Engelhardt M, Lane H, Evans TRJ, Plummer R, Kristeleit R, Lopez J, Aceto N.

Br J Cancer. 2018 Aug;119(4):487-491. doi: 10.1038/s41416-018-0186-7. Epub 2018 Aug 1.

13.

Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma.

Baxter MA, Glen H, Evans TR.

Future Oncol. 2018 Aug;14(20):2021-2029. doi: 10.2217/fon-2017-0689. Epub 2018 May 22. Review.

PMID:
29783903
14.

CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.

Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI, Wilkinson RW, Biankin AV, Barry ST, Balkwill FR, Sansom OJ.

Cell Rep. 2018 May 1;23(5):1448-1460. doi: 10.1016/j.celrep.2018.03.131.

15.

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).

Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, Evans TRJ, Gastaud L, Linette G, Berking C, Schachter J, Rodrigues MJ, Shoushtari AN, Clemett D, Ghiorghiu D, Mariani G, Spratt S, Lovick S, Barker P, Kilgour E, Lai Z, Schwartz GK, Nathan P.

J Clin Oncol. 2018 Apr 20;36(12):1232-1239. doi: 10.1200/JCO.2017.74.1090. Epub 2018 Mar 12. Erratum in: J Clin Oncol. 2018 Dec 10;36(35):3528.

PMID:
29528792
16.

Stochastic Pharmacokinetic-Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA).

Convertino M, Church TR, Olsen GW, Liu Y, Doyle E, Elcombe CR, Barnett AL, Samuel LM, MacPherson IR, Evans TRJ.

Toxicol Sci. 2018 May 1;163(1):293-306. doi: 10.1093/toxsci/kfy035.

17.

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL.

Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.

PMID:
29433850
18.

RavN is a member of a previously unrecognized group of Legionella pneumophila E3 ubiquitin ligases.

Lin YH, Lucas M, Evans TR, Abascal-Palacios G, Doms AG, Beauchene NA, Rojas AL, Hierro A, Machner MP.

PLoS Pathog. 2018 Feb 7;14(2):e1006897. doi: 10.1371/journal.ppat.1006897. eCollection 2018 Feb.

19.

Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule.

Marchetti C, Zyner KG, Ohnmacht SA, Robson M, Haider SM, Morton JP, Marsico G, Vo T, Laughlin-Toth S, Ahmed AA, Di Vita G, Pazitna I, Gunaratnam M, Besser RJ, Andrade ACG, Diocou S, Pike JA, Tannahill D, Pedley RB, Evans TRJ, Wilson WD, Balasubramanian S, Neidle S.

J Med Chem. 2018 Mar 22;61(6):2500-2517. doi: 10.1021/acs.jmedchem.7b01781. Epub 2018 Feb 7.

20.

Immune checkpoint inhibitors: new strategies to checkmate cancer.

Wilson RAM, Evans TRJ, Fraser AR, Nibbs RJB.

Clin Exp Immunol. 2018 Feb;191(2):133-148. doi: 10.1111/cei.13081. Epub 2017 Dec 27. Review.

21.

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.

Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, Hacking N, Evans TRJ, Collins P, Hubner RA, Cunningham D, Primrose JN, Johnson PJ, Palmer DH.

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575. doi: 10.1016/S2468-1253(17)30156-5. Epub 2017 Jun 23. Erratum in: Lancet Gastroenterol Hepatol. 2017 Sep;2(9):e6.

22.

Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.

Vennin C, Chin VT, Warren SC, Lucas MC, Herrmann D, Magenau A, Melenec P, Walters SN, Del Monte-Nieto G, Conway JR, Nobis M, Allam AH, McCloy RA, Currey N, Pinese M, Boulghourjian A, Zaratzian A, Adam AA, Heu C, Nagrial AM, Chou A, Steinmann A, Drury A, Froio D, Giry-Laterriere M, Harris NL, Phan T, Jain R, Weninger W, McGhee EJ, Whan R, Johns AL, Samra JS, Chantrill L, Gill AJ, Kohonen-Corish M, Harvey RP, Biankin AV; Australian Pancreatic Cancer Genome Initiative (APGI), Evans TR, Anderson KI, Grey ST, Ormandy CJ, Gallego-Ortega D, Wang Y, Samuel MS, Sansom OJ, Burgess A, Cox TR, Morton JP, Pajic M, Timpson P.

Sci Transl Med. 2017 Apr 5;9(384). pii: eaai8504. doi: 10.1126/scitranslmed.aai8504.

23.

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.

Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, Roxburgh P, Giordano H, Jaw-Tsai S, Goble S, Plummer R.

Br J Cancer. 2017 Mar 28;116(7):884-892. doi: 10.1038/bjc.2017.36. Epub 2017 Feb 21.

24.

Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.

Evans TRJ, Van Cutsem E, Moore MJ, Bazin IS, Rosemurgy A, Bodoky G, Deplanque G, Harrison M, Melichar B, Pezet D, Elekes A, Rock E, Lin C, Strauss L, O'Dwyer PJ.

Ann Oncol. 2017 Feb 1;28(2):354-361. doi: 10.1093/annonc/mdw607.

PMID:
27998964
25.

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

Driscoll DR, Karim SA, Sano M, Gay DM, Jacob W, Yu J, Mizukami Y, Gopinathan A, Jodrell DI, Evans TR, Bardeesy N, Hall MN, Quattrochi BJ, Klimstra DS, Barry ST, Sansom OJ, Lewis BC, Morton JP.

Cancer Res. 2016 Dec 1;76(23):6911-6923. Epub 2016 Oct 6.

26.

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.

Soria JC, Gan HK, Blagden SP, Plummer R, Arkenau HT, Ranson M, Evans TR, Zalcman G, Bahleda R, Hollebecque A, Lemech C, Dean E, Brown J, Gibson D, Peddareddigari V, Murray S, Nebot N, Mazumdar J, Swartz L, Auger KR, Fleming RA, Singh R, Millward M.

Ann Oncol. 2016 Dec;27(12):2268-2274. doi: 10.1093/annonc/mdw427. Epub 2016 Oct 11.

PMID:
27733373
27.

Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.

Propper D, Jones K, Anthoney DA, Mansoor W, Ford D, Eatock M, Agarwal R, Inatani M, Saito T, Abe M, Evans TR.

BMC Cancer. 2016 Oct 10;16(1):779.

28.

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.

Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TR, Anthoney A, Ranson M, Boddy AV, Plummer R.

Eur J Cancer. 2016 Nov;68:1-10. doi: 10.1016/j.ejca.2016.08.026. Epub 2016 Sep 28.

PMID:
27693888
29.

Virotherapy: cancer gene therapy at last?

Bilsland AE, Spiliopoulou P, Evans TR.

F1000Res. 2016 Aug 30;5. pii: F1000 Faculty Rev-2105. doi: 10.12688/f1000research.8211.1. eCollection 2016. Review.

30.

Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.

Carotenuto P, Fassan M, Pandolfo R, Lampis A, Vicentini C, Cascione L, Paulus-Hock V, Boulter L, Guest R, Quagliata L, Hahne JC, Ridgway R, Jamieson T, Athineos D, Veronese A, Visone R, Murgia C, Ferrari G, Guzzardo V, Evans TRJ, MacLeod M, Feng GJ, Dale T, Negrini M, Forbes SJ, Terracciano L, Scarpa A, Patel T, Valeri N, Workman P, Sansom O, Braconi C.

Gut. 2017 Jul;66(7):1268-1277. doi: 10.1136/gutjnl-2016-312278. Epub 2016 Sep 12.

31.

Small Bowel Adenocarcinoma.

Aparicio T, Zaanan A, Mary F, Afchain P, Manfredi S, Evans TR.

Gastroenterol Clin North Am. 2016 Sep;45(3):447-57. doi: 10.1016/j.gtc.2016.04.004. Review.

PMID:
27546842
32.

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.

Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, Foth M, Bryson S, McDaid K, Wilson Z, Eberlein C, Candido JB, Clarke M, Nixon C, Connelly J, Jamieson N, Carter CR, Balkwill F, Chang DK, Evans TRJ, Strathdee D, Biankin AV, Nibbs RJB, Barry ST, Sansom OJ, Morton JP.

Cancer Cell. 2016 Jun 13;29(6):832-845. doi: 10.1016/j.ccell.2016.04.014. Epub 2016 Jun 2.

33.

Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.

Zhu AX, Kang YK, Rosmorduc O, Evans TR, Santoro A, Ross P, Gane E, Vogel A, Jeffers M, Meinhardt G, Peña CE.

Clin Cancer Res. 2016 Oct 1;22(19):4870-4879. Epub 2016 May 24.

34.

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.

Milojkovic Kerklaan B, Slater S, Flynn M, Greystoke A, Witteveen PO, Megui-Roelvink M, de Vos F, Dean E, Reyderman L, Ottesen L, Ranson M, Lolkema MP, Plummer R, Kristeleit R, Evans TR, Schellens JH.

Invest New Drugs. 2016 Jun;34(3):329-37. doi: 10.1007/s10637-016-0344-9. Epub 2016 Apr 2.

PMID:
27039386
35.

A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.

Graham JS, Boyd K, Coxon FY, Wall LR, Eatock MM, Maughan TS, Highley M, Soulis E, Harden S, Bützberger-Zimmerli P, Evans TR.

BMC Res Notes. 2016 Mar 12;9:161. doi: 10.1186/s13104-015-1778-4.

36.

The Impact of Landscape Complexity on Invertebrate Diversity in Edges and Fields in an Agricultural Area.

Evans TR, Mahoney MJ, Cashatt ED, Noordijk J, de Snoo G, Musters CJ.

Insects. 2016 Feb 3;7(1). pii: E7. doi: 10.3390/insects7010007.

37.

Intravital FRAP Imaging using an E-cadherin-GFP Mouse Reveals Disease- and Drug-Dependent Dynamic Regulation of Cell-Cell Junctions in Live Tissue.

Erami Z, Herrmann D, Warren SC, Nobis M, McGhee EJ, Lucas MC, Leung W, Reischmann N, Mrowinska A, Schwarz JP, Kadir S, Conway JRW, Vennin C, Karim SA, Campbell AD, Gallego-Ortega D, Magenau A, Murphy KJ, Ridgway RA, Law AM, Walters SN, Grey ST, Croucher DR, Zhang L, Herzog H, Hardeman EC, Gunning PW, Ormandy CJ, Evans TRJ, Strathdee D, Sansom OJ, Morton JP, Anderson KI, Timpson P.

Cell Rep. 2016 Jan 5;14(1):152-167. doi: 10.1016/j.celrep.2015.12.020. Epub 2015 Dec 24.

38.

Part 9: First aid: 2015 International Consensus on First Aid Science with Treatment Recommendations.

Zideman DA, Singletary EM, De Buck ED, Chang WT, Jensen JL, Swain JM, Woodin JA, Blanchard IE, Herrington RA, Pellegrino JL, Hood NA, Lojero-Wheatley LF, Markenson DS, Yang HJ; First Aid Chapter Collaborators.

Resuscitation. 2015 Oct;95:e225-61. doi: 10.1016/j.resuscitation.2015.07.047. Epub 2015 Oct 15. Review. No abstract available.

PMID:
26477426
39.

European Resuscitation Council Guidelines for Resuscitation 2015 Section 9. First aid.

Zideman DA, De Buck ED, Singletary EM, Cassan P, Chalkias AF, Evans TR, Hafner CM, Handley AJ, Meyran D, Schunder-Tatzber S, Vandekerckhove PG.

Resuscitation. 2015 Oct;95:278-87. doi: 10.1016/j.resuscitation.2015.07.031. Epub 2015 Oct 15. No abstract available.

PMID:
26477417
40.

European Resuscitation Council Guidelines for Resuscitation 2015: Section 1. Executive summary.

Monsieurs KG, Nolan JP, Bossaert LL, Greif R, Maconochie IK, Nikolaou NI, Perkins GD, Soar J, Truhlář A, Wyllie J, Zideman DA; ERC Guidelines 2015 Writing Group.

Resuscitation. 2015 Oct;95:1-80. doi: 10.1016/j.resuscitation.2015.07.038. Epub 2015 Oct 15. No abstract available.

PMID:
26477410
41.

Part 9: First Aid: 2015 International Consensus on First Aid Science With Treatment Recommendations.

Singletary EM, Zideman DA, De Buck ED, Chang WT, Jensen JL, Swain JM, Woodin JA, Blanchard IE, Herrington RA, Pellegrino JL, Hood NA, Lojero-Wheatley LF, Markenson DS, Yang HJ; First Aid Chapter Collaborators.

Circulation. 2015 Oct 20;132(16 Suppl 1):S269-311. doi: 10.1161/CIR.0000000000000278. Review. No abstract available. Erratum in: Circulation. 2017 Jun 13;135(24):e1143.

PMID:
26472857
42.

Host Cell-catalyzed S-Palmitoylation Mediates Golgi Targeting of the Legionella Ubiquitin Ligase GobX.

Lin YH, Doms AG, Cheng E, Kim B, Evans TR, Machner MP.

J Biol Chem. 2015 Oct 16;290(42):25766-81. doi: 10.1074/jbc.M115.637397. Epub 2015 Aug 27.

43.

A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours.

Venugopal B, Awada A, Evans TR, Dueland S, Hendlisz A, Rasch W, Hernes K, Hagen S, Aamdal S.

Cancer Chemother Pharmacol. 2015 Oct;76(4):785-92. doi: 10.1007/s00280-015-2846-0. Epub 2015 Aug 20.

PMID:
26289594
44.

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.

Miller BW, Morton JP, Pinese M, Saturno G, Jamieson NB, McGhee E, Timpson P, Leach J, McGarry L, Shanks E, Bailey P, Chang D, Oien K, Karim S, Au A, Steele C, Carter CR, McKay C, Anderson K, Evans TR, Marais R, Springer C, Biankin A, Erler JT, Sansom OJ.

EMBO Mol Med. 2015 Aug;7(8):1063-76. doi: 10.15252/emmm.201404827.

45.

Mining the genomes of exceptional responders.

Chang DK, Grimmond SM, Evans TR, Biankin AV.

Nat Rev Cancer. 2014 May;14(5):291-2. doi: 10.1038/nrc3723.

PMID:
25688402
46.

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M, Meinhardt G, Kang YK.

J Clin Oncol. 2015 Feb 20;33(6):559-66. doi: 10.1200/JCO.2013.53.7746. Epub 2014 Dec 29.

47.

A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.

Puzanov I, Lindsay CR, Goff L, Sosman J, Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A, Chan E, Evans TR.

Clin Cancer Res. 2015 Feb 15;21(4):701-11. doi: 10.1158/1078-0432.CCR-14-0303. Epub 2014 Sep 11.

48.

Plasma N-acetyl-glucosaminidase in advanced gastro-intestinal adenocarcinoma correlates with age, stage and outcome.

Hartmann D, von Figura G, Song Z, Harden S, Scott LC, Evans TR, Rudolph KL, Bilsland AE, Keith WN.

Future Oncol. 2015;11(2):193-203.

49.

A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer.

Roxburgh P, Lumsden GR, Paul J, Harden S, Sweeting L, James A, Crellin A, Morrison R, Evans TR, McDonald AC.

Cancer Chemother Pharmacol. 2014 Jul;74(1):131-9. doi: 10.1007/s00280-014-2470-4. Epub 2014 May 13.

PMID:
24819683
50.

Targeting mTOR dependency in pancreatic cancer.

Morran DC, Wu J, Jamieson NB, Mrowinska A, Kalna G, Karim SA, Au AY, Scarlett CJ, Chang DK, Pajak MZ; Australian Pancreatic Cancer Genome Initiative (APGI), Oien KA, McKay CJ, Carter CR, Gillen G, Champion S, Pimlott SL, Anderson KI, Evans TR, Grimmond SM, Biankin AV, Sansom OJ, Morton JP.

Gut. 2014 Sep;63(9):1481-9. doi: 10.1136/gutjnl-2013-306202. Epub 2014 Apr 9.

Supplemental Content

Loading ...
Support Center